TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01457950
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: double-blind phase: placebo subcutaneous injection, single dose
Study: NCT01790282
Drug: estradiol plus progesterone 100 mg IM injection
Normalized name: estradiol / progesterone Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
Study: NCT03887260
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
Study: NCT00035451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, twice daily for 6 months
Study: NCT01892761
Drug: Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03387943
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
Study: NCT02485652
Drug: HM61713
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
Study: NCT03206632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00546260
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of iv bolus prior to angiography
Study: NCT00002598
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002598
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00511433
Drug: NOMAC-E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles.
Study: NCT02908685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
Study: NCT00283426
Drug: Soluble beta-1,3/1,6-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01065051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT02465749
Drug: Compound thrombosis capsule sig: 1.5g/tid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound thrombosis capsule sig: 1.5g/tid
Study: NCT02465749
Drug: Vitamin B sig: 10mg/tid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B sig: 10mg/tid
Study: NCT03258281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo administered subcutaneously
Study: NCT02526524
Drug: Met DR
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin delayed-release tablets
Study: NCT02526524
Drug: Met IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin immediate-release tablets
Study: NCT02526524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01503606
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin 500mg po bid after randomization for one week
Study: NCT01503606
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin 500mg po bid after randomization until delivery
Study: NCT00789581
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2
Study: NCT00789581
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m2
Study: NCT01046604
Drug: Lovaza group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
Study: NCT01783574
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01783574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00666497
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
Study: NCT00666497
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
Study: NCT04421911
Drug: Ketoprofen topical
Normalized name: ketoprofen topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen topical for 21days
Study: NCT00256815
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03115853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for Aliskerin
Study: NCT01967017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00693017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)
Study: NCT01069861
Drug: sildanefil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
Study: NCT02312232
Drug: levodopa, carbidopa, ODM-104
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03176472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mL liquid formulation placebo
Study: NCT00825058
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration 12 hours intervals
Study: NCT02709187
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT03546166
Drug: Picato 0.05% Topical Gel
Normalized name: Picato 0.05% Topical Gel (Trunk and Extremities Only)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
Study: NCT01847391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet(s) to match GS-6615 administered orally once daily
Study: NCT04008732
Drug: MED2005
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
Study: NCT04008732
Drug: Nitrostat 0.6Mg Sublingual Tablet
Normalized name: Nitrostat 0.6mg Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
Study: NCT03848208
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo oral tablet
Study: NCT03622112
Drug: AZD7594 DPI 55μg/50μg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-steroidal and selective modulator of the GR.
Study: NCT03622112
Drug: AZD7594 DPI 99 µg/90 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-steroidal and selective modulator of the GR.
Study: NCT03622112
Drug: AZD7594 DPI 198 µg/180 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-steroidal and selective modulator of the GR.
Study: NCT03622112
Drug: AZD7594 DPI 396 µg/360 µg once daily.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-steroidal and selective modulator of the GR.
Study: NCT03622112
Drug: AZD7594 DPI 792 µg/720 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-steroidal and selective modulator of the GR.
Study: NCT03622112
Drug: Placebo for AZD7594 once daily.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for AZD7594
Study: NCT03622112
Drug: FF 100 µg once daily (open-label)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate
Study: NCT00820482
Drug: Menopur®, Ferring
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 UI/day of Hp-hMG (Menopur®)
Study: NCT00820482
Drug: rFSH (Gonal®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
Study: NCT01571661
Drug: GSK189075A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Study: NCT03634566
Drug: N-Acetylecysteine
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
Study: NCT03634566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer acetate continuous infusion at the same rate for 2 days.
Study: NCT03872830
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours.
Study: NCT01147926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Prucalopride tablet orally once daily.
Study: NCT00297102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00320255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered once daily
Study: NCT06082596
Drug: BEBT-908 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle.
Study: NCT03087942
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg
Study: NCT03087942
Drug: QAW39A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg
Study: NCT03087942
Drug: QAW39A2107
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg
Study: NCT00773786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 1 week (added to maintenance tiotropium)
Study: NCT03943550
Drug: RO7049665
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of RO7049665 will be administered SC.
Study: NCT03943550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered SC.
Study: NCT01524432
Drug: Anti-fungal agent (Clotrimazole) loaded microcapsules
Normalized name: Aardora Anti-Fungal Maximum Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
Study: NCT01524432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug loaded microcapsules socks
Study: NCT01485900
Drug: SAR407899A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT01167010
Drug: Foraseq
Approvals — FDA: no, EMA: no, PMDA: no
Description: foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Study: NCT03403985
Drug: Calcium Hydroxide (Ca(OH)2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 will be used in this group
Study: NCT00792662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inactive pill.
Study: NCT01316276
Drug: Liposomal amikacin for inhalation
Normalized name: amikacin liposomal Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
Study: NCT02361424
Drug: PXT00864
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate
Study: NCT02361424
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02442453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
Study: NCT03142724
Drug: [18F]MNI-968
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
Study: NCT01573312
Drug: ASO3 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
Study: NCT00383643
Drug: Matching Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00218296
Drug: Usual Care Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine replacement therapy
Study: NCT00990327
Drug: Adenosine SPECT-MPI
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
Study: NCT01893372
Drug: Hypomethylating Agent (HMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
Study: NCT03834506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01474590
Drug: doxycycline 200mg
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, 2 capsules once daily in the morning with aglass of water and with food
Study: NCT02885454
Drug: Drospirenone/ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
Study: NCT01688947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
Study: NCT01643850
Drug: MCS110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
Study: NCT01643850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
Study: NCT00000419
Drug: Premarin and Provera
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02152059
Drug: BIBF1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
Study: NCT01015235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion-once over 4 hours
Study: NCT00747487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01960855
Drug: ABT-494
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 capsule administered orally twice daily (BID).
Study: NCT01960855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ABT-494 capsule administered orally twice daily (BID).
Study: NCT03488888
Drug: Normal Saline 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
Study: NCT00387179
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg, pill, once
Study: NCT00387179
Drug: Methylxanthine
Normalized name: Methylxanthine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.9 mg/kg, pill, once
Study: NCT00517439
Drug: RO4588161
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg po bid for 24 weeks
Study: NCT00517439
Drug: RO4588161
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg po bid for 24 weeks
Study: NCT00517439
Drug: RO4588161
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg po bid for 24 weeks
Study: NCT01174004
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, tablet, once daily by mouth for 6 weeks
Study: NCT00037648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03352453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study: NCT00858897
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
Study: NCT01898104
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04460924
Drug: Integrase strand transfer inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
Study: NCT01330979
Drug: AR-12286 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT02220023
Drug: INOmax Inhalation
Normalized name: INOmax Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02492945
Drug: 3ml-Rejuvinex
Approvals — FDA: no, EMA: no, PMDA: no
Description: They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
Study: NCT04178993
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each arm, subjects will receive placebo capsules.
Study: NCT02492945
Drug: 3ml-15%-dextrose solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
Study: NCT04143217
Drug: SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 200 to 600 mg/day
Study: NCT01962987
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
Study: NCT04371640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT00607113
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg By Mouth Daily For 21 Days
Study: NCT04620382
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT01044212
Drug: Bowel medications
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
Study: NCT02636244
Drug: SHAPE Gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00075387
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00975104
Drug: AMG 745 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 745 0.3 mg/kg IV QW
Study: NCT00975104
Drug: AMG 745 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 745 1.0 mg/kg IV QW
Study: NCT00975104
Drug: AMG 745 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 745 3.0 mg/kg IV QW
Study: NCT00975104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV QW
Study: NCT01082510
Drug: Bacille Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
Study: NCT01082510
Drug: uracil-tegafur
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
Study: NCT00915369
Drug: Nanoxel (Paclitaxel Nanoparticle formulation )
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.